Radius Health
950 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-551-4000
Fax: 617-551-4701
Website: http://www.radiuspharm.com/
Email: info@radiuspharm.com
About Radius Health
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
YEAR FOUNDED:
October 3, 2003
LEADERSHIP:
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
JOBS:
Please click here for Radius Health job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
190 articles with Radius Health
-
Radius Health Announces Pricing Of $300 Million Of 3.00% Convertible Senior Notes Due 2024
8/9/2017
-
Radius Health Announces Proposed Public Offering Of $300 Million Of Convertible Senior Notes Due 2024
8/8/2017
-
Radius Health Reports Second Quarter 2017 Financial And Operating Results And Provides Business Update
8/4/2017
-
Radius Health's Longtime CEO Out, Former Novo Nordisk A/S Exec Named New Leader
7/18/2017
-
Radius Health Announces New Employment Inducement Grant
7/18/2017
-
Radius Health Announces License And Development Agreement For Abaloparatide-SC With Teijin Limited In Japan
7/13/2017
-
Radius Health To Announce Second Quarter 2017 Financial Results, Host Conference Call And Live Webcast On August 3, 2017
7/7/2017
-
Radius Health Presents Positive Data From A Fully Enrolled Ongoing Phase I Study For Investigational Drug Elacestrant (RAD1901) At The 2017 ASCO
6/5/2017
-
Radius Health's Osteoporosis Drug Meets All Primary and Secondary Endpoints in Phase III Test
5/25/2017
-
Radius Health Announces New Employment Inducement Grant
5/16/2017
-
Radius Health Appoints Pharmaceutical Executive Jose Carmona As Chief Financial Officer
5/15/2017
-
Radius Health Reports First Quarter 2017 Financial And Operating Results
5/1/2017
-
FDA Approves Radius Health’s TYMLOS (Abaloparatide), A Bone Building Agent For The Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture
4/28/2017
-
Radius Health Announces Presentations At Upcoming Conferences And Its Plans To Announce First Quarter Financial Results On May 3, 2017
4/6/2017
-
Radius Health Release: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
4/3/2017
-
Radius Health Falls on PDUFA Extension for Abaloparatide-SC
3/10/2017
-
Radius Health Reports Fourth Quarter And Full Year 2016 Financial And Operating Results
2/24/2017
-
Radius Health Release: Mayo Clinic Proceedings Publishes Positive Results From The Activextend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis
2/1/2017
-
Radius Health To Announce Fourth Quarter And Full Year 2016 Financial Results, Host Conference Call And Live Webcast On February 23, 2017
1/31/2017
-
Radius Health Presents Positive Phase I Data For Investigational Drug RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) 2016
12/8/2016